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Abstract Failure to follow asthma management guidelines may result in poor asthma control for many patients.The
Asthma Insights andRealityin Europe (AIRE) survey, amulti-nationalsurveyassessing thelevelof asthmacontrolfromthe
patient’sperspectiveinsevenWestern Europeancountries, previouslydemonstratedthattheGlobal Initiative forAsthma
(GINA) guideline goalswerenot achieved inWestern Europe and that both adults and childrenwith asthmawere poorly
controlled.Using additional data on asthma management practices from each of the seven countries in the AIRE survey,
we compared variations in asthmamorbidity and asthmamanagement practices across countries to provide insight into
thereasons forpoor asthma control.Asthmamanagementpractices and asthma control amongadults andchildrenwith
currentasthmawere suboptimalineachofsevencountries surveyed.Amongpatientswithsymptomsofseverepersistent
asthma, over 40% reportedtheir asthmawaswellorcompletelycontrolled.School absence dueto asthmawasreported
byupto 527% ofchildrenandupto 276%of adultreportedworkabsencedueto asthma.Lung functiontestinginthepast
year was uncommon: ranging from135% of children in the U.K. to 688% of adults in Germany.Written asthmamanage-
ment plans were used by less than 50% of adults and less than 61% of children in all seven countries.Most adults (495^
730%) and a large proportion of children (384^706%) had follow-upvisits for their asthma onlywhenproblems devel-
oped.The ratio of recent inhaled corticosteroid use to recent short-acting b-agonist usewas inappropriate (o1) among
patients with symptoms of severe asthma in all countries.This disparity was greatest among adults in Italy and France,
where recent inhaled corticosteroid use was reported by less than one in nine patients reporting recent use of short-
acting bronchodialators (IS:SABo011).Management practices di¡er between countries and additional public health in-
terventions andresourcesmaybenecessary to reduce patient su¡ering.Furthere¡orts to fully implement asthmaman-
agementguidelines are required to improve asthma control in Europe.r2002 Elsevier Science Ltd.
doi:10.1053/rmed.2001.1241, available online at http://www.idealibrary.comon
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Asthma is a severe chronic disease which remains poorly
controlled in Western Europe (1). Clinical practice guide-
lineshavebeendeveloped tohelpphysiciansbettermanage
patients by presenting them with optimal management
practicesbasedon a systematic reviewof current evidence
about treatment options for a given disease (2). In recent
years, several national and international guidelines, includ-
ing the Global Initiative for Asthma (GINA) (3) have been
developed to improve the quality of care for patients withReceived 30May 2001, accepted in revised form 25 September 2001and
published online18 January 2002.
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Parts of this paper have been presented at the AmericanThoracic
Societymeeting inToronto,Canada,May 5^10, 2000.asthma and reduce the public health burden associated
with this disease (4).The GINA guidelines specify that ef-
fective long-termcontrolof asthmamaybe achievedby se-
lecting appropriate medications, treating asthma attacks,
identifying and avoiding asthma triggers, educating pa-
tients to manage their condition, and by regular monitor-
ing andmodifying of asthma care (3).
In a previous publication using data from the Asthma
Insights and Reality in Europe (AIRE) study, we demon-
strated that the GINA guideline goals are not currently
being achieved inWestern Europe and that inboth adults
and children asthma is poorly controlled (1).The present
paper uses additional information on asthma manage-
ment practices from each of the seven countries sur-
veyed and compares the variations in morbidity and
clinical management practices across countries to pro-
vide insight about the potential causes of poor asthma
control currently observed inWestern Europe.
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Themethods of theAIRE studyhavebeendescribed pre-
viously (1). Brie£y, the objective of the survey was to in-
terview patients (adults and parents of children younger
than16 years)withphysician-diagnosed asthma, andwith
current symptoms or asthma medication, about their
asthma-related knowledge, attitudes, behaviour and
health outcomes. Patients were identi¢ed by systematic
telephone screening of a national random digit dialling
sample of households with telephones in seven European
countries: France, Germany, Italy, The Netherlands,
Spain, Sweden and the U.K. The study design required
400 completed interviews with current asthma patients
in each of the seven countries to ensure equal sample
precision (for 80% power, 5% error).
All participants were interviewed after consenting to
participate in the survey.The questionnaire was derived
from theAmericanThoracic Society (ATS) questionnaire
(5). It was developed in English, translated into the
national language of each country and back-translated in
English by an independent translator to ensure consis-
tency.The questionnaire collected demographic charac-
teristics and information on access to medical care,
healthcare utilization, asthma symptoms, missed work/
school, asthma management practices, medication use,
and patient perception of asthma control and severity.
Data analysis
Acombined symptom severity index, basedupon the se-
verity classi¢cation in the GINA guidelines (3), was de-
rived from the reported frequency of daytime
symptoms, night-time symptoms, exertion-induced
symptoms, severe episodes and total symptom fre-
quency in the past 4 weeks and it has been outlined in a
previous report (1). Severe persistent asthma was indi-
cated by the presence of daytime symptoms more than
three times a day or night-time sleep disruption on at
least most nights. Moderate persistent asthma was de-
¢nedas daytime symptomsrtwiceperdayor night-time
sleep disruption at least twice a week. Mild persistentTABLE 1. Sampling strategyand demographic characteristics byc
France Germany Italy
Total screened (n) 8537 21823 11688
Total quali¢ed (n) 498 525 467
Eligible response rate (%) 837 762 856
Total surveypopulation (n) 402 400 400
Mean age (SD) (yr) 286 (206) 376 (214) 345 (226
Female (%) 532 535 555
Urban or suburban
residence (%)
864 761 891
SD, standard deviation.asthmawas de¢ned as daytime symptoms at least twice
a week or night-time sleep disruption at least twice per
month. Mild intermittent asthma was de¢ned as fewer
symptoms than those formild persistent asthma.
Recent asthma management was determined by pa-
tient-reported information on lung function testing,
peak £ow meter use, specialist visits, use of written
asthmamanagementplans, reasons for visiting thephysi-
cian and use of both inhaled corticosteroids and quick-
relief bronchodilator medications. Asthma morbidity
was determined by patient reported frequency of work/
school absence, urgentcare, emergencyroomvisits, phy-
sician visits and hospitalizations.
Asthma management practices and morbidity were
compared across each of the seven countries surveyed
relative to the rest of the AIRE population. All analyses
were presented separately for adults and children to al-
low for the potentially modifying e¡ects of di¡erent
treatment guidelines used for these patient groups and
information by proxy in children. Pearson’s chi-square
test and Student’s t-test (not pooled) were used to com-
pare proportions andmeans, respectively. All testswere
performed on unweighted data, two-tailed and consid-
ered signi¢cantly di¡erent at the 005 level.
RESULTS
Sample population
Table1describes characteristics of the samplepopulation
in each country. One or more current asthma patients
were identi¢ed in 3488 households and full interviews
were completed with 2803 current asthma patients or
their parents (804%). Age and sex distributions were si-
milar across all countries. Over 65% of all participants
lived in either urban or suburban residences.
Characteristics of current asthmatics across
countries
The samples of children and adults of the countries
involved were similar with respect to age, sex, age atountry
The Netherlands Spain Sweden U.K.
9429 12 329 6628 3446
478 490 520 510
837 816 769 872
400 401 400 400
) 321 (209) 354 (229) 350 (220) 321 (222)
553 591 557 570
657 937 670 732
TABLE 2. Demographic and asthma-relatedvariables bycountry, in children and adults
France Germany Italy The Netherlands Spain Sweden U.K.
Children (n) 145 80 106 117 86 93 126
Female (%) 448 w288 387 410 360 409 476
Mean (SD) asthma diagnosis age 34 (30) w46 (31) w29 (34) 29 (31) 32 (34) 39 (35) 35 (32)
Mean (SD) duration of asthma 51 (34) 51 (35) 51 (40) 51 (40) w59 (34) w43 (35) 55 (36)
School absence in last year (%) 517 438 425 487 535 w344 381
Current symptom severity (%)
Severe persistent 117 175 142 179 163 129 167
Moderate persistent 152 138 85 162 140 75 135
Mildpersistent 172 188 170 274 81 194 159
Mild intermittent 559 500 604 385 616 602 540
Adults (n) 257 320 294 283 315 307 274
Mean age (SD) (yrs) w399 (173) 446 (180) 440 (185) 421 (163) 425 (206) 431 (184) 428 (187)
Female (%) 580 597 616 611 654 603 613
Current smoker (%) w237 194 146 180 165 199 157
Mean (SD) asthma diagnosis age w 209 (180) w279 (190) 245 (187) w207 (174) 241 (193) w273 (205) 262 (215)
Mean (SD) duration of asthma 190 (141) 167 (143) 195 (153) w215 (150) 185 (172) w158 (140) w166 (145)
Work absence in last year (%) 167 175 180 w276 168 w127 164
Current symptom severity (%) w w w
Severe persistent 148 278 214 254 194 153 186
Moderate persistent 202 244 235 254 276 205 201
Mildpersistent 202 194 221 166 152 221 193
Mild intermittent 447 284 330 325 378 420 420
wPo005 is signi¢cant for the comparisonbetween samples and the restofthe AIREpopulation.
For categorical variables the wabove the group represents statistical signi¢cance for the entire subgroup compared to the total
population.
144 RESPIRATORYMEDICINEasthma diagnosis, duration of asthma and current symp-
tom severity (Table 2).However, the children surveyed in
Germany were signi¢cantly older and predominantly
male relative to rest of the AIRE population. French
adults surveyed were younger and more were current
smokers than the rest of the AIRE population. Duration
of asthma among adults was longer in the Netherlands
and shorter in Germany, Sweden, and the U.K. relative
to other countries.France and Sweden had fewer severe
asthmatics comparedwith the rest of the adult AIRE po-
pulation (Table 2).
Patients’perception of their overall asthma control did
notmatch their reported symptom severity. Among pa-
tientswith symptoms of severepersistent asthma (Fig.1),
over 50% of the children and over 40% of the adults in
most countries felt their asthmawas well or completely
controlled. Germany, France and Spain reported the
greatest disparities between actual and perceived con-
trol, with over 75% of children and 50% of adults with
symptoms of severe persistent asthma reporting well
or completely controlled asthma. Additionally, school
absence due to asthma in the past year was reported by
up to 53%of children (Spain) andup to 28%of adults (The
Netherlands) reported work absence in the past year
due to asthma (Table 2).Asthmamanagement practices and use of
healthcare services
Asthmamanagementpractice anduse of health carevar-
ied widely between countries (Table 3).Unscheduled ur-
gent care visits were most common in Spain and least
common in Sweden among both children and adults.
Compared with the rest of the AIRE population, emer-
gency room visits in the past year were required by a
higher percentage of children in Spain and Sweden and a
lower percentage of children in the Netherlands, U.K.
and Germany. Hospitalization rates of children in the
Netherlands, Sweden, and the U.K. were 30^50% lower
than the other countries surveyed. Similar to adults,
therewas a higher rate of emergency roomvisits among
children in Spain and Sweden relative to the rest of AIRE
population.
Lung function testing among children was least com-
mon in theU.K. andmost common inGermany (Table 3).
Fewchildren in theU.K. had an asthmamanagementplan
(87%) or used a peak £ow meter at least once a week
(87%). In contrast, 605% of children in Spain had an
asthmamanagementplanbut only 58% used a peak £ow
meter at least once a week. Similarly, a high proportion
of Italian children had a written action plan (528%), but
FIG. 1. Proportion of well or complete controlreported by severe persistent asthmatics amongchildren (&) and adults ( ) in each
country.
TABLE 3. Asthmamanagementpractices anduse of health services inpast year bycountry, in children and adults
Subjects (%)
France Germany Italy The Netherlands Spain Sweden U.K.
Children (n) 145 80 106 117 86 93 126
Unscheduledurgentcare inpast year 317 275 311 *402 *500 *140 278
ERvisit in past year 152 *88 189 *68 *395 *333 *79
Hospitalisation inpast year 110 100 123 *34 128 65 48
LF test inpast year *482 *600 *217 *393 *267 365 *135
Peak £owmeter at leastonce aweek *34 *125 *19 *43 *58 *43 *87
Writtenplan for asthma *441 238 *528 *197 *605 *237 *87
GP seenmostoften for asthma *566 388 *217 *607 *174 *204 *817
Doctor visits for asthma 0^5 year1 *483 550 632 *700 675 *861 *705
Specialist visit neveroronly if problems *435 430 *482 *539 *407 *548 *794
Follow-upvisits only whenhaving trouble 469 413 575 *393 *384 *387 *706
Adults (n) 257 320 294 283 315 307 274
Unscheduledurgentcare inpast year 233 253 *187 *304 *340 *130 204
ERvisit in past year *47 *56 105 *49 *222 *169 80
Hospitalisation inpast year 43 *97 75 64 92 46 58
LF test inpast year *463 *684 *235 *516 *368 *488 *259
Peak £owmeter at leastonce aweek *31 *100 *48 *18 *16 *46 *131
Doctor writtenplan for asthma *323 213 *347 *155 *492 *101 *95
GP seenmostoften for asthma *720 659 *442 686 *498 655 *858
Doctor visits for asthma 0^5 year1 *607 *594 *646 735 178 *908 *526
Specialist visit neveroronly if problems *572 *454 *466 *622 *423 *828 *865
Follow-upvisits only whenhaving trouble 545 *534 *684 *527 *495 606 *730
*Po005 is signi¢cant for the comparison between samples andwiththe restofthe AIREpopulation.
ER, emergencyroom;LF, lung function;GP, generalpractitioner.
POORMANAGEMENTANDCONTROLOFASTHMAINSEVENEUROPEANCOUNTRIES 145only 19% used a peak £ow meter at least once a week.
The variation in adult lung function testing, peak £ow
meter use and possession of an asthma action plan was
generally similar to that seen among children. One ex-
ception was the low reported use of peak £ow meters
among adults in Spain (16%) and The Netherlands(18%). In every country except the U.K., adultswere less
likely to have had a written asthma management plan
than children.
Generalpractitionerswere theprincipal care giver for
asthma among for themajority of adults in all countries,
but provided treatment for themajority of children only
146 RESPIRATORYMEDICINEin the U.K., France and The Netherlands (Table 3). For
over 80% of all adults and children, their primary care gi-
ver was also their primary source of advice about their
asthma (not shown).Many children and adults had either
never seen an asthma specialist or only when they devel-
oped problems with their asthma. Across the countries
surveyed, a largeproportion of children and themajority
of adults only had follow-up visits when they were ex-
periencing troublewith their asthma.
Use of asthmamedication
Inhaled corticosteroids usewas highest in Sweden (Table
4) where it was signi¢cantly greater than in the rest of
the AIRE population among both adults and children at
most levels of asthma symptom severity.The proportion
of Swedish children using ICSwith symptoms suggestive
ofmoderate (714%) or severe (833%) persistent asthma
was approximately three and six times higher than simi-
lar rates inThe Netherlands, respectively. Likewise, re-
ported use of inhaled corticosteroids among adults
with severe persistent symptoms was approximately six
times higher in Sweden relative to France or Italy. In gen-
eral, reported use of short-acting bronchodilator (SAB)
medication in the past 4 weeks was high in all countries
but tended to be higher with increasing symptom sever-
ity (not shown).Theratio of inhaledcorticosteroiduse to
short-acting bronchodilator use was suboptimal (o1) in
all countries for both children [Fig. 2(a)] and adults [Fig.
2(b)]. This disparity was greatest among adults with
symptoms of severe persistent asthma in Italy and
Francewhere recent inhaled corticosteroids usewas re-
ported by less than one in nine patients reporting use of
quick-relief medications (ICS:SABo011).
DISCUSSION
To our knowledge, the AIRE survey was the largest
survey ever conducted in Europe to estimate asthmaTABLE 4. Percentage children and adults reportinguse of inhaled
France Germany Italy
Children
Severe persistent 235 214 267
Moderate persistent 182 273 667
Mildpersistent 360 267 333
Mild intermittent 136 150 *47
Adults
Severe persistent *79 303 *79
Moderate persistent 269 295 *145
Mildpersistent *77 355 154
Mild intermittent 104 176 *93
*Po005 is signi¢cant for the comparison between samples andcontrol among children and adults. Suboptimal asthma
control was found among children and adults in all coun-
tries andwas re£ectedby a high level of work and school
absence and a high rate of unscheduled doctor visits,
hospitalization or emergency department visits.
Furthermore, the level of care reported by patients in
each country did not meet the recommendations re-
quired to achieve appropriate asthma control as de-
scribed by the GINA guidelines. In particular, there was
insu⁄cient monitoring of asthma by doctors and pa-
tients themselves. Most disturbing was the evidence of
considerable under-use of inhaled corticosteroids by pa-
tients with moderate or severe persistent symptoms.
This implies that the asthma management guidelines
were either not being adequately followed by physicians
or patients were poorly compliant with this therapy.
Although the AIRE study was not an asthma preva-
lence study, we estimated prevalence among the
screened population to describe how representative
our samplewas across each country.The household pre-
valence of asthma was highest in the U.K. (148%) and
lowest in Germany (24%), and ranged from 36% to
58% in the other ¢ve countries surveyed. In agreement
with the ECHRS study in adults (6) and the ISAAC study
in children (7), we found the highest asthma prevalence
rate in the U.K. and it was at least two-fold greater than
that in anyof the other six European countries surveyed.
Our results on asthma drug usage rates also agreedwith
the ECHRS study, which found that asthma medication
use among adult asthmatics was lower in Italy, France
and Spain than in the Netherlands, Sweden and the U.K.
(8).Moreover, they con¢rm earlier reports of heteroge-
neity in asthma management practices within Europe
and in other parts of the world (8^10).The similarity of
our study results to previous surveys indicated that the
AIRE sample was representative of the current asth-
matic population in these countries.
Moreover, this survey demonstrated insu⁄cientmon-
itoring of patient lung function using either clinic-based
spirometry or home peak-£ow monitoring. Regularcorticosteroids bycurrent symptom severityand bycountry
The Netherlands Spain Sweden U.K.
143 429 *833 238
263 333 714 353
219 286 389 350
178 94 *286 176
236 *98 *489 333
306 184 *397 200
277 167 353 358
207 118 *287 235
the restof the AIREpopulation.
FIG. 2. Ratio of inhaled corticosteroid to quick-reliefmedicationuse inthe past 4 weeks among (a) children and (b) adults.
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the asthma management guidelines because both
patients and physicians can have di⁄culties in recogniz-
ing asthma symptoms or their severity (11,12). We
found that a high proportion of patients not only
under-estimated the severity of their asthma symp-
toms but also substantially over-estimated their asthma
control. In addition, written asthma management plans
were generally uncommon, although they were
used more frequently for children than adults in most
countries.
In a recent, well-conducted case-control study (13),
written asthma plans were associatedwith a 70% reduc-
tion in the risk of death, and regular use of a peak £ow
meter with a 35% reduction.Therefore, as concluded in
a previous meta-analysis (14), the implementation of
these simple interventions in themanagement of asthma
lead to clinically relevant bene¢ts for the patients, as ad-
vocated in the GINA guidelines.Anti-in£ammatory drugs play a central role in the
long-termmanagement of asthma, and asthmamanage-
ment guidelines recommend inhaled corticosteroids for
all patients with persistent asthma (3). In the AIRE study,
we found considerable under-use of inhaled corticoster-
oids among both adults and children experiencing symp-
toms consistent with persistent asthma. Additionally,
the use of inhaled corticosteroids according to asthma
symptom severity di¡ered widely between the seven
European countries surveyed.One of the most notable
di¡erenceswas the relatively high proportion of patients
in Sweden taking inhaled corticosteroids.This may have
been due to local recommendations which suggest the
initiation of inhaled corticosteroids at a lower threshold
of as-needed bronchodilator use than in other countries
(15).The increased use of inhaled corticosteroids in Swe-
den in recent years has been associatedwith a signi¢cant
decline in hospitalization rates and asthma-related
morbidity (16). The large cross-country di¡erences in
148 RESPIRATORYMEDICINEthereporteduse of inhaledcorticosteroids suggests that
the prescribing of inhaled corticosteroids may di¡er be-
tween countries and are additional evidence that asthma
management guidelines may not be applied uniformly
across Europe.
A striking ¢nding of our survey was that, except for
asthmatic children in Sweden, less than half of the pa-
tients (adults and children) with symptoms suggestive of
severe persistent asthma in each country reportedusing
inhaled corticosteroids in the past 4 weeks.This may be
becausephysicians hadnotprescribed corticosteroids or
patients were not compliant with therapy. Previous re-
search has shown that non-compliance to asthmamedi-
cation is common in the seven countries included in the
AIRE survey, being highest inThe Netherlands (approxi-
mately 75%) and lowest in Sweden (approximately 50%)
(17). It is well recognized that patient compliance with
prescribed asthma medication is poor and that this may
be due to a variety of factors including poor patient un-
derstanding of the role of therapy (18). Nevertheless,
poor patient compliance with medication is a major fac-
tor contributing to poor asthma control regardless of
asthma severity (19).
Another important ¢nding of our survey was that use
of quick relief bronchodilation therapy was inappropri-
ately high relative to the use of inhaled corticosteroids
and the severity of asthma symptoms. There was
an over-reliance on quick-relief medication in all coun-
tries surveyed. These results suggested that overall
asthma medication use was better among children
than adults. Previous studies in the U.K. have suggested
that the inhaled corticosteroid to bronchodilator ratio
can be taken as a measure of the quality of asthma care,
and an increase in the ratio has been associated with a
reduction in hospitalization for asthma (20,21).The sub-
stantial di¡erences in asthma drug use ratios across Eur-
opean countries may re£ect di¡erences in knowledge of
asthma medications between these countries, and indi-
cates the need for improved patient education about
the role of inhaled corticosteroids inmaintaining asthma
control.
The AIRE survey revealed that few patients see an
asthma specialist. It is generally accepted thatmost asth-
ma care shouldbeprovided at theprimarycare level, but
patientswhomaybene¢t fromconsultationwith an asth-
ma specialist should be identi¢ed and referred accord-
ingly (22). Patients treated by specialists are more likely
to receive anduse inhaled corticosteroids (23). Access to
medical care in general and asthma-related care in parti-
cular varied between countries, and this may have con-
tributed to the di¡erences in asthma control and
morbidity found across countries in the present study.
Regular follow-up visits are an important factor in the
process of asthma care, and lack of regular medical fol-
low-up has been associated with under-use of inhaled
anti-in£ammatory treatment by patients (4).Although theGINAguidelineshavebeendisseminated
in all countries surveyed in the AIRE survey, our results
suggest that the level of adherence to asthma manage-
ment guidelines is low. Similar conclusions were reached
in earlier studies of asthmatics (23) and the general po-
pulation (9). Although doctors may agree with asthma
treatment guidelines, this is not always re£ected in their
prescribing behaviour or management practices (24).
Moreover, a recent study demonstrated that physicians
were poor at estimating asthma severity and their use
of lung function tests and anti-in£ammatory agents was
inadequate; this may have contributed to their poor ad-
herence to the guidelines (25). Further e¡orts must be
made to improve asthma management in general prac-
tice, to adhere more closely to international guidelines,
to improve asthma control amongpatients and to reduce
the need for acute healthcare services.
The limitations of the AIRE study methodology have
been previously described (1). Brie£y, the sample con-
sistedof currently treatedor recently symptomatic asth-
matic patients with telephone access in predominantly
urban and suburban households. Current asthmatics or
their parents were surveyed to reduce the risk of recall
bias because of poor disease awareness. The method of
telephone sampling by random digit dialling is well ac-
cepted and has already been used in several population
studies of the burden of asthma (26^28). There is in-
creasing evidence that patients of lower socio-economic
status have reduced access to medical care (29) and in-
creased asthma hospitalization (30).Therefore, the pro-
blem of poor control andmanagement of asthmamaybe
evenworse than found in our study, as familieswithout a
home telephonemaybe of lower socio-economic status.
Other potential factors contributing to the di¡erences
seen between countries include di¡erent dissemination
anduse of guidelines, cultural variations in symptomper-
ception and seeking medical care, environmental di¡er-
ences (31), and di¡erences in physician understanding of
asthma and its treatment (32). Seasonal di¡erences are
unlikely to have contributed to the di¡erences observed
between countries, as the survey was conducted over a
short period during the same season in all countries.
In summary, the AIRE study demonstrated that asth-
ma management practices in the countries surveyed are
highly variable and do not appear to achieve the stan-
dards expected by the GINA treatment guidelines. This
is re£ected in the poor level of asthma control demon-
stratedby adults and children participating in the survey.
One of the real challenges over the next few years will
be the e¡ective implementation of asthma management
guidelines. In particular, physicians need to improve the
use of inhaled corticosteroids by patients and to make
more use of written asthma action plans for patients to
self-manage their asthma. This should be coupled with
regular medical review and monitoring of lung function.
Education andpublic healthresources shouldbe targeted
POORMANAGEMENTANDCONTROLOFASTHMAINSEVENEUROPEANCOUNTRIES 149to increase awareness about the severity of asthma and
to ensureproper treatmentof this condition to avoidpo-
tentially severe consequences.
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